Harmony Biosciences Grapples With A Leadership Transition That Spooked Investors

Harmony Biosciences remains under pressure since the company announced its CEO transition. Will an upcoming narcolepsy drug change that?

Investors Business Daily • Oct 28, 2026

Harmony Biosciences Holdings, Inc. (HRMY) Reports Next Week: Wall Street Expects Earnings Growth

Harmony Biosciences (HRMY) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Investment Research • Oct 28, 2026

Are Investors Undervaluing Harmony Biosciences (HRMY) Right Now?

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

Zacks Investment Research • Oct 22, 2026

HRMY or ARGX: Which Is the Better Value Stock Right Now?

Investors interested in Medical - Biomedical and Genetics stocks are likely familiar with Harmony Biosciences Holdings, Inc. (HRMY) and argenex SE (ARGX). But which of these two stocks offers value investors a better bang for their buck right now?

Zacks Investment Research • Oct 22, 2026

Revisiting Former Stock Picks Marriott, Logitech, Harmony Biosciences

Technical indicators have turned bullish for the Barron's Investor Circle stock picks.

Barrons • Oct 22, 2026

Harmony Biosciences: A Cash Machine With A Patent Ruling Hanging Over It

Harmony Biosciences is rated Buy with a 12-month price target of $43, reflecting strong cash generation and WAKIX growth. HRMY's valuation is supported by WAKIX's robust performance, cash reserves, and limited downside if patents hold through 2030. Key risks include the pending AET patent litigation and management turnover, with significant near-term binary events ahead.

Seeking Alpha • Oct 21, 2026

Harmony Biosciences to Report Third Quarter 2026 Financial Results on November 4, 2026

PLYMOUTH MEETING, Pa., Oct. 20, 2026 (GLOBE NEWSWIRE) -- Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY) today announced that it will report third quarter 2026 financial results on Wednesday, November 4, 2026, before the open of the U.S. financial markets. Harmony will host a conference call and webcast on November 4, 2026, at 8:30 a.m. ET to discuss the results.

GlobeNewsWire • Oct 20, 2026

HRMY Stock Gains 27.6% in Six Months: Is There More Room for Growth?

Harmony Biosciences gains 27.6% in six months as Wakix sales surge and pipeline advances, with new formulations and clinical milestones offering further growth opportunities.

Zacks Investment Research • Oct 16, 2026

Harmony Bio CEO Plans His Exit, And Shares Take An Unharmonious Hit

Harmony Biosciences stock took a tumble Monday after its announced the transition of current CEO Jeffrey Dayno at the end of the year.

Investors Business Daily • Oct 12, 2026

Why Harmony Biosciences Stock Got Mashed on Monday

This, despite the move being expected. The company's new CEO will take up the post at the beginning of next year.

The Motley Fool • Oct 12, 2026